Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.722
-0.018 (-2.46%)
Apr 29, 2026, 9:33 AM EDT - Market open
Werewolf Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 35 | 31 | 66 | 140 | 63 | 328 | |
| Market Cap Growth | 10.21% | -53.38% | -52.79% | 121.66% | -80.81% | - | |
| Enterprise Value | -12 | 2 | -20 | 62 | -62 | 160 | |
| Last Close Price | 0.74 | 0.63 | 1.48 | 3.86 | 2.05 | 11.91 | |
| PS Ratio | - | - | 34.99 | 7.01 | 3.84 | - | |
| PB Ratio | 1.45 | 1.24 | 0.90 | 1.25 | 0.52 | 2.15 | |
| P/TBV Ratio | 1.45 | 1.24 | 0.90 | 1.25 | 0.52 | 2.15 | |
| EV/Sales Ratio | - | - | - | 3.10 | - | - | |
| Debt / Equity Ratio | 0.38 | 0.38 | 0.51 | 0.47 | 0.12 | 0.10 | |
| Net Debt / Equity Ratio | -1.92 | -1.92 | -1.01 | -0.74 | -0.94 | -0.93 | |
| Net Debt / EBITDA Ratio | 0.81 | 0.81 | 1.03 | 2.13 | 2.09 | 2.85 | |
| Net Debt / FCF Ratio | 0.79 | 0.79 | 1.31 | 2.47 | 2.59 | 3.27 | |
| Asset Turnover | - | - | 0.01 | 0.12 | 0.10 | - | |
| Quick Ratio | 1.58 | 1.58 | 7.31 | 7.00 | 5.68 | 13.27 | |
| Current Ratio | 1.62 | 1.62 | 7.45 | 7.14 | 5.84 | 13.57 | |
| Return on Equity (ROE) | -123.88% | -123.88% | -76.33% | -31.98% | -39.12% | -41.31% | |
| Return on Assets (ROA) | -38.63% | -38.63% | -30.48% | -15.11% | -20.64% | -22.71% | |
| Return on Capital Employed (ROCE) | -182.50% | -182.50% | -65.90% | -26.10% | -41.10% | -29.90% | |
| Earnings Yield | -169.13% | -197.79% | -106.92% | -26.75% | -85.38% | -15.22% | |
| FCF Yield | -167.66% | -196.07% | -85.58% | -23.89% | -70.14% | -13.21% | |
| Buyback Yield / Dilution | -6.73% | -6.73% | -23.04% | -23.50% | -56.40% | -1736.32% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.